Open AccessThis article is
- freely available
Anti-Infectious Agents against MRSA
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
* Author to whom correspondence should be addressed.
Received: 16 October 2012; in revised form: 3 December 2012 / Accepted: 14 December 2012 / Published: 24 December 2012
Abstract: Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described.
Keywords: MRSA; anti-infectious agents; peptidoglycan; teichoic acid; virulence factors
Citations to this Article
Cite This Article
MDPI and ACS Style
Koyama, N.; Inokoshi, J.; Tomoda, H. Anti-Infectious Agents against MRSA. Molecules 2013, 18, 204-224.
Koyama N, Inokoshi J, Tomoda H. Anti-Infectious Agents against MRSA. Molecules. 2013; 18(1):204-224.
Koyama, Nobuhiro; Inokoshi, Junji; Tomoda, Hiroshi. 2013. "Anti-Infectious Agents against MRSA." Molecules 18, no. 1: 204-224.